Effects of fish oil supplementation on apolipoprotein B100 production and lipoprotein metabolism in normolipidaemic males

Abstract

Objective: To evaluate the effects of four weeks of ®sh oil supplementation on apolipoprotein B100 production and lipoprotein metabolism in normolipidaemic males. Design and subjects: Very low density lipoprotein (VLDL) apolipoprotein B100 (apoB100) kinetics in ten healthy, white males, aged 22±43 y (mean 32 y) were investigated using a 13 C-leucine technique and gas chromatography-mass spectrometry before and after ®sh oil supplementation. Intervention: All subjects received 10 g (1.8 g EPA, 1.2 g DHA)ad of ®sh oil concentrate for four weeks. Results: Fish oil supplementation resulted in a decrease of total plasma VLDL (mean AE s.d. 1.11 AE 0.41 vs 0.87 AE 0.28 mmolal, P`0.05) and triacylglycerol concentrations (0.74 AE 0.27 vs 0.48 AE 0.21 mmolal, P`0.01). VLDL apoB100 pool size was decreased without alteration of the fractional synthetic rate but a signi®cant decrease of apoB100 production (2.23 AE 0.90 vs 1.54 AE 0.52 mgadlah, P`0.02). Following ®sh oil supplementation plasma concentrations of glucose and insulin as well as lipoprotein and hepatic lipase activities were unchanged. Fasting plasma concentrations of non-esteri®ed fatty acid (NEFA) were decreased (0.45 AE 0.12 vs 0.33 AE 0.10 mmolal, P`0.05). Conclusions: Dietary supplementation with ®sh oil in healthy males results in decreased VLDL-triacylglycerol concentrations through a decrease in VLDL particle synthesis. The decrease in NEFA substrate supply also contributes. Sponsorship: Fish oil (Maxepa 1 ) was supplied by Seven Seas Ltd, Hull, England, free of charge. Dr OAF Bodamer was funded by the`Deutsche Forschungsgemeinschaft' (Bo 1193a1-2).

Regulatory Effects of HMG CoA Reductase Inhibitor and Fish Oils on Apolipoprotein B-100 Kinetics in Insulin-Resistant Obese Male Subjects With Dyslipidemia

“…Effect of fish oils on apoB metabolism. Animal and human studies have shown that fish oils lower plasma triglycerides by inhibiting hepatic VLDL-apoB secretion (18,20). This finding agrees with our observation that the VLDL-apoB pool size and secretion rate decreased with fish oils.…”

“…Our pretreatment data were consistent with those from previous kinetics studies. The independent effects of statins (34,35) or fish oils (18,20,36,37) on apoB kinetics have been examined only in nonobese, insulinsensitive subjects. The present study extends previous studies to insulin-resistant subjects.…”

“…In addition, fish oils decrease the hepatic pool of triglycerides by suppressing transcription of the SREBP-1c gene, thereby inhibiting de novo synthesis of fatty acids and triglycerides (19). Accordingly, fish oils decrease hepatic VLDL-apoB secretion in both humans and experimental animals (18,20). The kinetic effects of fish oils on apoB metabolism in insulin-resistant, obese subjects have not been investigated.…”

Thematic review series: Patient-Oriented Research. Design and analysis of lipoprotein tracer kinetics studies in humans

“…The first models used to describe VLDL apoB kinetics used a monoexponential function, equivalent to a singlecompartment model, to determine FCR (55)(56)(57). Al-though these models provided a good description of the experimental data, with the exception of the early time points, using such a model to simulate an exogenously labeled VLDL kinetics study would reveal that the apoB tracer curve was monoexponential.…”

Thematic review series: Patient-Oriented Research. What we have learned about VLDL and LDL metabolism from human kinetics studies

“…At the same time, the conversion of VLDL to LDL was reduced. The effect of fish oil supplements on VLDLapoB-100 kinetics was investigated by Bordin et al (19). Four weeks of feeding fish oil supplements resulted in a decreased production of VLDL-apoB-100 and a decreased triglyceride concentration.…”